Capstone Therapeutics Corp. (CAPS)
USD 3.0
(-11.76%)
USD 3.0
(-11.76%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.74 Million USD | -122.44% |
| 2022 | 4.23 Million USD | -15.69% |
| 2021 | 5.02 Million USD | 90.16% |
| 2020 | 2.64 Million USD | 465.28% |
| 2019 | -723 Thousand USD | -82.12% |
| 2018 | -397 Thousand USD | 73.08% |
| 2017 | -1.47 Million USD | -4.98% |
| 2016 | -1.4 Million USD | 49.5% |
| 2015 | -2.78 Million USD | 36.25% |
| 2014 | -4.36 Million USD | -5.92% |
| 2013 | -4.12 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 113 Thousand USD | 117.68% |
| 2024 Q1 | -639 Thousand USD | 62.23% |
| 2023 Q1 | -629 Thousand USD | -294.14% |
| 2023 Q3 | -48 Thousand USD | -107.75% |
| 2023 Q2 | 619 Thousand USD | 198.41% |
| 2023 FY | - USD | -122.44% |
| 2023 Q4 | -1.69 Million USD | -3425.0% |
| 2022 Q1 | 130 Thousand USD | -73.47% |
| 2022 Q4 | 324 Thousand USD | -81.09% |
| 2022 Q3 | 1.71 Million USD | -17.13% |
| 2022 FY | - USD | -15.69% |
| 2022 Q2 | 2.06 Million USD | 1490.0% |
| 2021 Q1 | -1.04 Million USD | -969.39% |
| 2021 Q4 | 490 Thousand USD | -84.82% |
| 2021 Q3 | 3.22 Million USD | 37.14% |
| 2021 FY | - USD | 90.16% |
| 2021 Q2 | 2.35 Million USD | 324.52% |
| 2020 FY | - USD | 465.28% |
| 2020 Q3 | 1.69 Million USD | 0.0% |
| 2020 Q4 | -98 Thousand USD | -105.79% |
| 2019 FY | - USD | -82.12% |
| 2019 Q1 | -750 Thousand USD | -135.11% |
| 2019 Q2 | -605 Thousand USD | 19.33% |
| 2018 Q2 | 1.37 Million USD | 380.86% |
| 2018 Q1 | -491 Thousand USD | -2.29% |
| 2018 Q3 | -593 Thousand USD | -143.0% |
| 2018 FY | - USD | 73.08% |
| 2018 Q4 | -319 Thousand USD | 46.21% |
| 2017 Q1 | -336 Thousand USD | -20.43% |
| 2017 FY | - USD | -4.98% |
| 2017 Q3 | -487 Thousand USD | -183.14% |
| 2017 Q2 | -172 Thousand USD | 48.81% |
| 2017 Q4 | -480 Thousand USD | 1.44% |
| 2016 Q1 | -337 Thousand USD | 59.2% |
| 2016 Q2 | -333 Thousand USD | 1.19% |
| 2016 Q4 | -279 Thousand USD | 38.82% |
| 2016 FY | - USD | 49.5% |
| 2016 Q3 | -456 Thousand USD | -36.94% |
| 2015 Q3 | -377 Thousand USD | 52.64% |
| 2015 Q4 | -826 Thousand USD | -119.1% |
| 2015 Q1 | -783 Thousand USD | -1.56% |
| 2015 Q2 | -796 Thousand USD | -1.66% |
| 2015 FY | - USD | 36.25% |
| 2014 Q1 | -1.04 Million USD | -53.91% |
| 2014 Q2 | -1.35 Million USD | -29.85% |
| 2014 Q4 | -771 Thousand USD | 35.64% |
| 2014 Q3 | -1.19 Million USD | 11.46% |
| 2014 FY | - USD | -5.92% |
| 2013 Q2 | -981 Thousand USD | 24.54% |
| 2013 Q1 | -1.3 Million USD | 0.0% |
| 2013 Q4 | -677 Thousand USD | 41.69% |
| 2013 FY | - USD | 0.0% |
| 2013 Q3 | -1.16 Million USD | -18.35% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 97.536% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 70.484% |
| SQZ Biotechnologies Company | -64.14 Million USD | 97.272% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 89.925% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.861% |
| Mesoblast Limited | -62.38 Million USD | 97.195% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -13.929% |
| Genus plc | 73.7 Million USD | 102.374% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 73.531% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 50.663% |
| Marizyme, Inc. | -34.28 Million USD | 94.895% |
| ContraFect Corporation | -64.99 Million USD | 97.308% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 80.05% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 61.336% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -24.839% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 33.824% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 24.693% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -237.808% |
| Accustem Sciences Inc. | -3.74 Million USD | 53.289% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 96.371% |
| EV Biologics, Inc. | -1.26 Million USD | -38.107% |
| Q BioMed Inc. | -617.62 Thousand USD | -183.342% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 148.992% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -176.721% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 23.396% |
| Biomind Labs Inc. | -1.03 Million USD | -69.156% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 117.718% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 75.563% |
| Skye Bioscience, Inc. | -13.54 Million USD | 87.083% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -17.654% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -6899.996% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 54.947% |
| IMV Inc. | -35.52 Million USD | 95.074% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 88.973% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 30.055% |
| GB Sciences, Inc. | -1.41 Million USD | -23.249% |
| Alpha Cognition Inc. | -9.7 Million USD | 81.969% |
| HST Global, Inc. | -5303.00 USD | -32900.17% |
| CSL Limited | 4.78 Billion USD | 100.037% |
| Halberd Corporation | -74.27 Thousand USD | -2255.981% |
| Enzolytics Inc. | -2.12 Million USD | 17.532% |
| Resverlogix Corp. | -11.74 Million USD | 85.096% |
| Affymax, Inc. | -14.29 Million USD | 87.758% |
| SYBLEU INC | -141.57 Thousand USD | -1136.128% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 42.867% |
| argenx SE | -216.02 Million USD | 99.19% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 96.838% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 243.796% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -16.752% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 561.931% |
| AVAX Technologies, Inc. | -6.11 Million USD | 71.371% |
| Zenith Capital Corp. | -8.6 Million USD | 79.665% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.296% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -9945.342% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 28.468% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -894.18% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 95.585% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 39.495% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -67.254% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 26126.16% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 8.897% |
| BioStem Technologies, Inc. | -7.55 Million USD | 76.832% |
| ONE Bio Corp. | 13.61 Million USD | 112.855% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -866.38% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 14.925% |
| Agentix Corp. | -1.37 Million USD | -27.574% |
| LadRx Corporation | 412.28 Thousand USD | 524.465% |
| Cell Source, Inc. | -4.27 Million USD | 59.041% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -376.552% |
| Regen BioPharma, Inc. | 1.46 Million USD | 219.376% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -86.776% |
| NovAccess Global Inc. | -1.03 Million USD | -69.115% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 119.766% |
| Itoco Inc. | -1.86 Million USD | 6.367% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -360.987% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -56.81% |
| Kadimastem Ltd | -2.62 Million USD | 33.318% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -631.758% |
| CytoDyn Inc. | -18.02 Million USD | 90.293% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -2114.376% |
| Mobile Lads Corp. | -2.24 Million USD | 21.915% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -14210.238% |
| Qrons Inc. | -40.08 Thousand USD | -4266.156% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -260.321% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 431.796% |
| Rebus Holdings, Inc. | -951 Thousand USD | -84.017% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -64.782% |
| International Stem Cell Corporation | 202 Thousand USD | 966.336% |
| Bioxytran, Inc. | -3.82 Million USD | 54.19% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -3224.466% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 28.918% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 95.121% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -3788.887% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 36.085% |
| Neutra Corp. | -181.24 Thousand USD | -865.533% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 91.319% |
| PureTech Health plc | -11.62 Million USD | 84.949% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 91.318% |
| IXICO plc | -707 Thousand USD | -147.525% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 77.228% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 96.38% |
| CSL Limited | 4.73 Billion USD | 100.037% |
| Cellectis S.A. | -92.63 Million USD | 98.111% |